Skip to main content

Plaintiff Opposes Exatech’s Summary Judgment Motion

Plaintiff Opposes Exatech’s Summary Judgment Motion

Plaintiff Opposes Exatech’s Summary Judgment Motion

Introduction

A plaintiff filed an opposition on September 4, before Judge Pamela Reeves of the U.S. District Court for the Eastern District of Tennessee, responding to the summary judgment announced for Exatech Inc.'s AcuMatch hip implant lawsuit last month.

The company had announced a summary judgment declaring that there was no written warranty that the device would last longer than 15 years; hence, the case could be excluded under Texas law. However, the plaintiff stated that his case must be considered as an exception to the Texas statute of repose because the company's sales representatives vouched for the device to last 15 to 20 years. He accuses that Exatech purposely covered up design defects in their hip implant device thereby affecting the limitation period. The plaintiff underwent a total arthroplasty of his left hip on September 14, 2001, during which an AcuMatch M-Series Femoral Stem was implanted in his hip. In 2016, the device broke into half and required him to undergo a total hip revision surgery. He filed a product liability action against the company on August 24, 2017, in the Northern District of Texas.

Hip implant failures are on the rise across the U.S. with several affected patients accusing the implant makers of illegally marketing the product as safe to use. Zimmer, Biomet, Stryker and many other manufacturers involved in the class action litigation for failing to provide an inadequate warning about the alleged device breakage.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!